Dana-Farber Research News 03.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 16 - 28.

By
March 15, 2026
21 min

Dana-Farber

Overview

This report summarizes recent research findings from Dana-Farber faculty, highlighting significant studies on hyperinflammatory syndromes, cancer care for older adults, and brain metastases treatment strategies. Key insights include the role of interferon gamma in HLH and the comparative effectiveness of stereotactic radiation versus whole brain radiation.

Background

The management of hyperinflammatory syndromes and brain metastases represents critical challenges in oncology. Understanding the role of biomarkers like interferon gamma can enhance patient stratification and treatment approaches. Additionally, addressing the unique needs of older adults with cancer is essential for improving outcomes in this growing patient population.

Data Highlights

No numerical data available in the provided source material.

Key Findings

Interferon gamma is implicated in mortality associated with adult HLH.
Older adults represent over 40% of cancer patients in the US, yet face significant barriers to trial enrollment.
Less than 3% of older cancer patients participate in clinical trials, highlighting a gap in research.
Stereotactic radiation may improve symptom severity compared to whole brain radiation with hippocampal avoidance.
Study findings suggest a need for scalable strategies to support older adults with cancer.

Clinical Implications

Clinicians should consider the role of interferon gamma as a potential biomarker in managing HLH. Furthermore, there is an urgent need to develop inclusive research strategies that address the complexities of treating older adults with cancer.

Conclusion

The findings from Dana-Farber's recent research underscore the importance of tailored treatment approaches in oncology, particularly for vulnerable populations such as older adults and those with hyperinflammatory syndromes.